ARK Genomic Revolution ETF (ARKG) maintains a "Buy" rating, driven by strong technicals and momentum despite a premium valuation. ARKG has outperformed XLV and SPY over the past year, returning 23% ...
The ARK Genomic Revolution ETF offers unique, actively managed exposure to innovative genomics companies, focusing on small- and mid-caps for high-growth potential. ARKG's active management and high ...
Hosted on MSN
Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD
・On Thursday, ARK bought a total of 56,769 shares of Intellia, with 48,178 shares purchased by its ARKK ETF and 8,591 shares through its ARKG ETF. ・NTLA stock was its top 23 investment as of Dec. 31, ...
This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...
In trading on Thursday, the iShares U.S. Home Construction ETF is outperforming other ETFs, up about 3.8% on the day. Components of that ETF showing particular strength include shares of LGI Homes, up ...
In trading on Friday, the Sprott Silver Miners & Physical Silver ETF is outperforming other ETFs, up about 3.5% on the day. Components of that ETF showing particular strength include shares of Avino ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
This fund is not currently covered by a Morningstar analyst. How do we decide what funds to cover? We’re committed to covering those funds that are most relevant to investors and that hold a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results